Published in Lab Business Week, July 2nd, 2006
Asuragen, a spin-off of Ambion Inc., will dedicate the funds towards general operating needs and to pursue strategic licenses relating to the development of its cancer diagnostic and therapeutic programs.
This initial round of investment, led by San Francisco, California, based Telegraph Hill Partners, included Houston based Growth Capital Partners and other firms that invested in Ambion, Inc.
Rollie Carlson joins Asuragen as president from Abbott Laboratories, has extensive experience in molecular diagnostic and pharmaceutical business areas. Most...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.